Trulieve Cannabis Index Fund Ownership Update

“When will the institutions show up?” They’re already here. Trulieve Cannabis has crossed a threshold long closed to most U.S. plant-touching cannabis operators, securing a place in the machinery of passive investing after its June listing on the New York Stock Exchange. The move followed federal rescheduling of medical marijuana to Schedule III and the company’s redomicile to Delaware, clearing the principal obstacles that had kept such firms confined to over-the-counter markets and specialized thematic funds. By mid-September, Trulieve had been added to the S&P Total Market Index and the S&P Completion Index. Those inclusions have already produced measurable ownership in several of the largest broad-market and completion-index trackers, illustrating how quickly rules-based capital can respond once listing and domicile requirements are satisfied.

$VXF 1,921,805 shares (9/30/26)
$VTI 1,396,100 shares (9/30/26)
$SCHA 896,026 shares (10/19/26)
$ITOT 224,144 shares (10/19/26)
$SCHB: 102,394 shares (10/19/26)
TOTAL: 4,540,469 shares worth $46.68M as of 10/19

The holdings that have appeared are modest relative to the multi-hundred-billion-dollar assets of the funds involved, yet they mark a structural change for the sector. Because these vehicles rebalance toward their benchmarks on a regular schedule, the positions largely reflect mechanical buying rather than discretionary views on the cannabis business. For a company whose public trading history had been dominated by retail and specialist investors, the shift introduces a new, relatively inelastic source of demand.

Attention is now turning to the Russell 2000 $IWM. FTSE Russell’s December reconstitution — the first December review in more than three decades under the index family’s semi-annual calendar — will rank companies by market capitalization as of the October 30 close. Preliminary addition and deletion lists are scheduled for publication after the market close on November 13, with the reconstituted indexes becoming effective after the close on December 11. At a market capitalization near $2 billion, Trulieve sits comfortably inside the small-cap range established in the prior reconstitution, when the cutoff between the Russell 1000 and Russell 2000 stood at roughly $5.7 billion. Market participants tracking the process note that the company has already satisfied the domicile, exchange-listing, and investability screens that previously excluded U.S. cannabis operators. Should it appear on the preliminary list, passive vehicles benchmarked to the Russell 2000 would be expected to purchase shares in the weeks leading up to the effective date, adding another layer of forced demand on top of the S&P-related positions already established.

Whether that inclusion materializes remains a question of ranking and final eligibility rather than a foregone conclusion. Still, the sequence already completed by Trulieve — NYSE listing, S&P index entry, and documented ownership by major completion and total-market funds — has demonstrated that the practical barriers separating plant-touching cannabis companies from mainstream passive capital can be removed in a matter of months once regulatory and corporate-structure conditions align. For the broader sector, the episode supplies a measurable precedent: index eligibility is no longer purely theoretical, and the resulting ownership, while still limited, is beginning to appear in the daily holdings of the funds that dominate U.S. equity allocation.